Dendritic cell-based cancer immunotherapy

Dendritic cell is the most effective antigen presenting cells in human. We performed a couple of dendritic cell-based cancer immunotherapy in Tokyo Women's Medical University. Autologous tumor lysates or synthetic peptides are pulsed with dendritic cells to make the dendritic cell vaccine. Tumo...

Full description

Saved in:
Bibliographic Details
Published inNihon rinshō Vol. 68; no. 6; p. 1107
Main Author Aruga, Atsushi
Format Journal Article
LanguageJapanese
Published Japan 01.06.2010
Subjects
Antigen Presentation
Cancer Vaccines - therapeutic use
Dendritic Cells - immunology
Humans
Immunotherapy
Neoplasms - immunology
Neoplasms - therapy
T-Lymphocytes - immunology
Online AccessGet more information

Cover

More Information
Summary:Dendritic cell is the most effective antigen presenting cells in human. We performed a couple of dendritic cell-based cancer immunotherapy in Tokyo Women's Medical University. Autologous tumor lysates or synthetic peptides are pulsed with dendritic cells to make the dendritic cell vaccine. Tumor-pulsed dendritic cell vaccine (TP-DC) or peptide pulsed dendritic cell vaccine (PP-DC) are safe and useful in the patients with advanced cancer. Antigen unpulsed immature dendritic cell could work at a cancer vaccine when they inject into tumors in vivo. Dendritic cell-activated T cells (DCAT) in vitro are also useful tools for cancer treatment. In order to obtain a good evidence of dendritic cell-based immunotherapy, we need to perform the randomized trial near the future.
ISSN:0047-1852